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ABSTRACT
Brain metastases are common and devastating complications of both breast cancer and melanoma.
Although mammary carcinoma brain metastases are more frequent than those originating from
melanoma, this latter has the highest tropism to the brain. Using static and dynamic in vitro
approaches, here we show that melanoma cells have increased adhesion to the brain endothelium
in comparison to breast cancer cells. Moreover, melanoma cells can transmigrate more rapidly and
in a higher number through brain endothelial monolayers than breast cancer cells. In addition,
melanoma cells have increased ability to impair tight junctions of cerebral endothelial cells. We also
show that inhibition of Rac or PI3K impedes adhesion of breast cancer cells and melanoma cells to
the brain endothelium. In addition, inhibition of Rac or PI3K inhibits the late phase of transmigration
of breast cancer cells and the early phase of transmigration of melanoma cells. On the other hand,
the Rac inhibitor EHT1864 impairs the junctional integrity of the brain endothelium, while the PI3K
inhibitor LY294002 has no damaging effect on interendothelial junctions. We suggest that targeting
the PI3K/Akt pathway may represent a novel opportunity in preventing the formation of brain
metastases of melanoma and breast cancer.
Abbreviations: BBB, blood-brain barrier; CEC, cerebral endothelial cell; CNS, central nervous system; D3,
(hCMEC/D3) human cerebral microvascular endothelial cells, clone D3; GEF, guanine nucleotide exchange
factor; PI3K, phosphoinositide 3-kinase; RBEC, rat brain endothelial cell; ROCK, Rho-kinase
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Introduction
Brain metastases – which are usually late, but devastating
20 complications of cancer – most frequently originate from
lung cancer, breast cancer and melanoma. Tumor cells
successfully inﬁltrating the brain parenchyma overcome
several obstacles, including survival in the circulation,1
extravasation through brain capillaries (reviewed in:2)
25 and resisting deleterious signals of the reactive brain
stroma.3 However, cancer cells able to migrate into and
to survive in the brain will beneﬁt of a supportive and
protective microenvironment, including the dense vascu-
lature with the opportunity of vessel co-option4 and che-
30 moprotection mediated by astrocytes and endothelial
cells.5 As a consequence, brain metastases have a poor
prognosis. Therefore, inhibiting extravasation of meta-
static cells into the brain would be of great clinical
beneﬁt.
35 Diapedesis of metastatic cells through the capillaries
of the brain implies adhesion of tumor cells to the
luminal surface of cerebral endothelial cells (CECs), fol-
lowed by a recently described, not yet fully characterized
step called incorporation into the monolayer,6 and ﬁnally
40the transmigration step itself. CECs are interconnected
by a continuous layer of tight junctions and form the
blood-brain barrier (BBB). The BBB restricts the free
movement of solutes between the blood and the central
nervous system, and represents an impediment for cellu-
45lar elements (leukocytes and metastatic cells) to reach
the brain parenchyma (reviewed in:7). We have previ-
ously shown that melanoma cells are able to disrupt the
tight junctions of CECs making possible their transmi-
gration through the brain endothelium.8 It is not under-
50stood however, whether breast cancer cells are able to
disrupt the tight junctions or migrate preferentially
transcellularly. In fact, transcellular migration of tumor
cells has only been described in case of breast cancer cells
during intravasation into an in vitro vascular network9
55and migration through umbilical cord endothelial cells.10
CONTACT Imola Wilhelm wilhelm.imola@brc.mta.hu
Color versions of one orQ2 more of the ﬁgures in this article can be found online at www.tandfonline.com/kcam.
© 2016 Taylor & Francis Group, LLC
CELL ADHESION & MIGRATION
2016, VOL. 0, NO. 0, 1–13
http://dx.doi.org/10.1080/19336918.2015.1122156
However, to our knowledge, no data on the transmigra-
tion pathway of breast cancer cells through BBB endo-
thelial cells exist.
Our previous results indicated that during transmi-
60 gration through the brain endothelium, melanoma
cells favor the mesenchymal type of cell movement.11
This is characterized by an elongated morphology,
increased proteolytic activity and is dependent on Rac
activity.12 On the other hand, the amoeboid type of
65 tumor cell migration is characterized by rounded
morphology and extensive RhoA signaling. Tumor
cells can switch between these 2 movement types
depending on the environment they move in.13 By
inhibiting Rho/ROCK signaling, and therefore trigger-
70 ing the mesenchymal phenotype, a signiﬁcant increase
in the number of melanoma cells migrating through
CECs could be induced.11 Here we aimed to compare
melanoma and breast cancer cells in respect of mes-
enchymal vs. amoeboid migration through the brain
75 endothelium. The question whether tumor cells prefer
Rho/ROCK or Rac-dependent transendothelial migra-
tion is of clinical importance, since inhibitors of both
Rho/ROCK (e.g. fasudil) and Rac pathways14 are
emerging as potential therapeutic agents.
80 The Rac pathway has been shown to be regulated by
phosphoinositide 3-kinase (PI3K) in breast cancer
cells.15 Moreover, the PI3K/Akt/mTOR pathway is prob-
ably the most important in respect of anti-cancer treat-
ment targets.16 It has been shown that dysregulation of
85 the PI3K signaling pathway is associated with the devel-
opment of one-third of human cancers, including breast
cancers17 and melanomas.18 Aberrant activation of the
PI3K pathway promotes carcinogenesis, tumor angio-
genesis and resistance to therapies,19 and plays a role in
90 cell motility as well.20
Therefore, the ﬁrst aim of our study was to com-
pare the adhesion and transmigration properties of
melanoma and breast cancer cells. The second aim
was to understand the role of Rac signaling and of
95 amoeboid vs. mesenchymal phenotype in the transmi-
gration of breast cancer cells through the BBB. The
third aim was to investigate whether PI3K inhibition
has an impact on the transmigration of tumor cells
through the cerebral endothelium during brain metas-
100 tasis formation.
Results
Adhesion and transmigration properties of
melanoma and breast cancer cells in vitro
Since melanoma cells have higher propensity to metasta-
105size to the brain than breast cancer cells, we aimed to
understand whether there is any difference in the inter-
action of melanoma cells or breast cancer cells with the
brain endothelium.
We ﬁrst aimed to compare the adhesion properties of
110melanoma and breast cancer cells to the brain endothe-
lium. 90 min after plating the tumor cells upon brain
endothelial cells, signiﬁcantly more melanoma cells than
breast cancer cells were able to attach to the endothelium
(Table 1). Therefore, we wanted to test whether the
115increased adhesion of melanoma cells in comparison to
breast cancer cells results in an increased transmigration
as well.
For studying the transmigration properties of mela-
noma and breast cancer cells in static conditions, we
120used a novel approach based on a time-lapse video setup
described in the Materials and methods section. This
innovative assay developed in our laboratory makes pos-
sible to follow the fate of each individual cell in time
(adhesion, migration, division, etc.). This approach elim-
125inates the drawbacks of assays using ﬁlter inserts, where
cells migrating through the endothelial monolayer but
not moving through the pores of the ﬁlter cannot be con-
sidered. Moreover, several cell types (including D3 cells)
cannot be properly grown on large pore-size ﬁlters due
130to the formation of a double monolayer on both sides of
the membrane.
Comparing the transmigration properties of mela-
noma and breast cancer cells using the static transmigra-
tion assay, we observed that fewer breast cancer cells
135than melanoma cells were able to migrate through the
brain endothelium (Table 2). The difference was signiﬁ-
cant: 27–28% of plated melanoma cells completed the
transmigration process, while only 16% of breast cancer
cells migrated through.
140To conﬁrm our results in physiologically more rele-
vant conditions, we constructed a dynamic transmigra-
tion model. Brain endothelial cells were cultured in a
microﬂuidic device (Figure 1A; described in details in
the Material and methods section) until conﬂuence
Table 1. Comparison of the adhesion of MDA-MB-231, MCF-7, A2058 and A375 cells to D3 brain endothelial monolayers. % of plated
cells is represented (mean and SD); p value was assessed using ANOVA and Bonferroni’s post-hoc test.
D3CMDA-MB-231 D3CMCF-7 D3CA2058 D3CA375
average 18.44% 18.15% 34.64% 35.05%
st dev 8.66% 8.92% 7.41% 0.75%
p <0.05vs. A2058 or A375 <0.05vs. A2058 or A375 <0.05 vs. MDA or MCF <0.05 vs. MDA or MCF
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145 (Suppl. video 1). After reaching conﬂuence, a slow, phys-
iologically relevant ﬂow of the culture medium was initi-
ated (300 ml/h, 1–2 dyn/cm2) for 24 h. Shear stress
induced elongation of endothelial cells (Suppl. Figure 1).
After injection of MDA-MB-231 or A2058 cells, the ﬂow
150was re-started with a rate of 100 ml/h, phase-contrast
Table 2. Comparison of transmigration of MDA-MB-231, A2058 and A375 cells through D3 brain endothelial monolayers under static
conditions. % of plated cells is represented (mean and SD); p value was assessed using Student’s test.
D3CMDA-MB-231 D3CA2058 D3CA375
average 15.78% 26.99% 28.28%
st dev 0.82% 2.54% 4.72
p <0.05 vs. A2058 OR A375 <0.05 vs. MDA-MB-231 <0.05 vs. MDA-MB-231
Figure 1. Dynamic transmigration experimental setup. (A): Schematic representation of the microﬂuidic device. (B): Images used for con-
structing the time lapse videos (presented in Suppl. videos 2 and 3). D3 cells were cultured until conﬂuence in the microﬂuidic device,
then tumor cells were injected and left under a continuous ﬂow of 100 ml/h for 6 h. Phase contrast images were taken every 5 min. Indi-
vidual tumor cells were marked as follows: white circle D no attachment, black circle D no transmigration, white arrow D transmigra-
tion in 20 min, black arrow D transmigration in >20 min, black box D division. The gray dotted stars delineate clusters of
transmigrating melanoma cells.
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images were taken and time-lapse videos were con-
structed to analyze the movements of the tumor cells
(Figure 1B, Suppl. videos 2 and 3).
In these conditions approximately 50% of breast can-
155 cer cells and 42.5% of melanoma cells showed no attach-
ment and were washed away by the ﬂow of the culture
medium in early stages of the experiment (Figure 1B:
white circles, Table 3: no attachment). The percentage of
tumor cells not washed away from the optical ﬁelds stud-
160 ied, but not able to transmigrate in 6 h, was signiﬁcantly
more in case of breast cancer cells than in case of mela-
noma cells (15% vs. 4.5%, respectively) (Figure 1B: black
circles, Table 3: no transmigration). Taken together, 53%
of melanoma and 35% of breast cancer cells transmi-
165 grated through the brain endothelial monolayer in these
conditions. The difference in the transmigration between
the 2 cell types was the most pronounced in early time
points: 23.5% of the total number of melanoma cells
migrated through the brain endothelium in the ﬁrst
170 20 min, while the percentage of breast cancer cells trans-
migrating in this time frame was only 3% (Figure 1B:
white arrows, Table 3: transmigr. in 20 min). Melanoma
cells tended to attach and transmigrate in small groups
(Figure 1B: gray dotted star), as we have previously
175 observed in static conditions.8 After transmigration, sev-
eral melanoma cells continued to move beneath and
between endothelial cells (as previously seen in static
conditions8), sometimes rounding up and ﬂattening
again (Figure 1B: cells 1 and 2). A few divisions were also
180 observed (Figure 1B: black boxes) and the daughter cells
usually transmigrated rapidly after division (Figure 1B:
cell 3).
Taken together, these results show that melanoma
cells are able to adhere to and migrate through the brain
185 endothelium more effectively than breast cancer cells.
This might be partly responsible for the higher propen-
sity of melanoma cells to metastasize to the brain.
Differences in the effects of melanoma cells and
breast cancer cells on the tight junctions of brain
190endothelial cells
We have previously observed that during transmigration
melanoma cells are able to disrupt the tight junctions of
cerebral endothelial cells and use (at least partly) the par-
acellular way of migration.8 We were interested to
195understand whether breast cancer cells are also able to
impair the junctional integrity of the cerebral endothe-
lium. Therefore, we performed claudin-5 immunostain-
ing on primary rat brain endothelial cell (RBEC)
monolayers challenged either with MDA-MB-231 breast
200cancer or with A2058 melanoma cells. As shown on
Figure 2, melanoma cells could breach the junctions of
RBECs as indicated by focal loss of claudin-5 staining.
This was not observed in case of breast cancer cells.
These data suggest that differences in the transendo-
205thelial migration of mammary carcinoma and melanoma
cells might be partly due to differences in their ability to
impair interendothelial junctions.
Inhibition of Rac or PI3K hampers the adhesion of
breast cancer cells and melanoma cells to the brain
210endothelium
We have previously shown that inhibition of the Rho/
ROCK pathway facilitates the adhesion of melanoma
cells, and this effect is reversed by the Rac inhibitor
EHT1864.11 We now aimed to understand whether
215the same mechanism applies for breast cancer cells
during adhesion to cerebral endothelial cells. In con-
trast to melanoma cells, ROCK inhibitors (10 mM
Y27632 or 10 mM fasudil) were not able to increase
the number of breast cancer cells adherent to the
220brain endothelium (Figure 3A). On the other hand,
the Rac inhibitor EHT1864 (20 mM) hampered the
Table 3. Comparison of transmigration of A2058 and MDA-MB-231 cells through D3 brain endothelial monolayers under dynamic condi-
tions. MDA-MB-231 breast cancer cells or A2058 melanoma cells were injected into the microchannels already containing conﬂuent D3
monolayers. Tumor cells were monitored for 6 h under a continuous medium ﬂow of 100 ml/h. Tumor cells were divided into four
groups: cells washed away by the ﬂow of the culture medium (no attachment), cells not transmigrating in 6 h (no transmigration), cells
migrating through the brain endothelium in the ﬁrst 20 min (transmigr. in 20 min) and cells transmigrating after 20 min (transmigr. in
>20 min). % of plated cells is represented (mean and SD); p value (comparing D3CMDA-MB-231 and D3CA2058) was assessed with
ANOVA and Bonferroni’s post-hoc test
D3CMDA-MB-231 no attachment no transmigration transmigr.in 20 min transmigr. In >20 min
average 50.00% 15.00% 2.80% 32.20%
st dev 4.24% 4.04% 1.73% 3.54%
D3CA2058
no attachment no transmigration transmigr.in 20 min transmigr. In >20 min
average 42.50% 4.50% 23.50% 29.50%
st dev 7.21% 1.00% 4.95% 5.12%
p <0.05 <0.05
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adhesion of both MDA-MB-231 and MCF-7 breast
cancer cells (Figure 3A and B). As expected, mainly
the number of elongated adherent cells was decreased,
225 which have a mesenchymal phenotype. When both
ROCK and Rac inhibitors were applied, a similar
reduction in the adhesion of tumor cells was seen as
with the Rac inhibitor alone (Figure 3A). In addition,
the PI3K inhibitor LY294002 in a concentration of
230 25 mM signiﬁcantly reduced the number of breast
cancer and melanoma cells attaching to the brain
endothelium. The reduction was approximately 40%
compared to control in case of both breast cancer
and melanoma cells, and mainly affected tumor cells
235 with elongated (ﬂattened, mesenchymal) phenotype
(Figure 3A-C). In case of A375 melanoma cells, which
presented a rounded morphology during adhesion,
LY294002 could also signiﬁcantly reduce the number
of adherent cells (Figure 3D).
240 Interestingly, when measuring the adhesion forces
using atomic force microscopy between MDA-MB-231
breast cancer and hCMEC/D3 brain endothelial cells, or
A2058 melanoma and hCMEC/D3 brain endothelial
cells, respectively, we could not observe any decrease in
245response to EHT1864 or LY294002 (Suppl. Figure 2).
Inhibition of Rac or PI3K impedes the transmigration
of breast cancer cells and melanoma cells through
the brain endothelium in static conditions
Since inhibition of Rac or PI3K decreased the adhesion
250of both melanoma and breast cancer cells, we tested the
effect of Rac or PI3K inhibitors on the transmigration of
melanoma and breast cancer cells through brain endo-
thelial monolayers as well (Figure 4). In this assay we
used 2 invasive melanoma cell lines (A2058 and A375)
255and the MDA-MB-231 breast cancer cell line, which is
more invasive than the MCF-7 cell line. Inhibition of
Rac with EHT1864 signiﬁcantly reduced the transmigra-
tion of both tumor cell types to approximately 20% in
case of breast cancer cells (Figure 4A) and to 15% in case
260of melanoma cells (Figure 4C). LY294002 had similar
effects: the transmigration percentage was approximately
30% and 40%, respectively, compared to control
(Figure 4B, D, E).
Figure 2. Effect of breast cancer and melanoma cells on the tight junctions of brain endothelial cells. MDA-MB-231 breast cancer cells or
A2058 melanoma cells labeled in red were plated onto conﬂuent RBEC monolayers and left for 5 h. Tight junctions of endothelial cells
were stained in green using anti-claudin-5 antibodies. Arrows indicate disappearance of claudin-5 staining.
B=w in print; colour online
Figure 3. Effect of Rac- or PI3K-inhibition on the adhesion of breast cancer cells or melanoma cells onto the brain endothelium. Fluores-
cently labeled MDA-MB-231 (A), MCF-7 breast cancer cells (B), A2058 (C) or A375 melanoma cells (D) were plated onto conﬂuent D3
monolayers and left for 90 min. After washing of non-adherent cells, attached tumor cells were counted. Results are expressed as % con-
trol and given as mean § SD. N D 3,  D P < 0.01, as assessed by ANOVA and Bonferroni’s post-hoc test.
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Inhibition of Rac or PI3K inhibits the late phase of
265 transmigration of breast cancer cells and the early
phase of transmigration of melanoma cells through
the brain endothelium in dynamic conditions
Using our dynamic model, we explored which step of
transmigration of breast cancer or melanoma cells
270 was inhibited by EHT1864 or LY294002. As previ-
ously discussed (Table 3), only 8% of total transmi-
grating breast cancer cells completed transmigration
in the ﬁrst 20 min (2.8% of 35%), while this was sig-
niﬁcantly higher in case of melanoma cells (44.34%,
275 i.e. 23.5% of 53%). This suggests that melanoma cells
can transmigrate more rapidly through the brain
endothelium than breast cancer cells (Figure 5). Nev-
ertheless, EHT1864 and LY294002 inhibited the rapid
transmigration of melanoma cells. However, in case
280 of breast cancer cells the number of cells transmigrat-
ing after 20 min was reduced by inhibitors of Rac
and PI3K (Figure 5).
Taken together, our results indicate that inhibition of
Rac or PI3K impairs the ability of both breast cancer and
285 melanoma cells to adhere to and to migrate through the
brain endothelium. Differences exist however, between
the velocities of the transmigration of the 2 tumor cell
types.
Effects of Rac and PI3K inhibitors on the viability,
290proliferation and migration of tumor cells and brain
endothelial cells
We wanted to exclude that the inhibitory effect of
EHT1864 and LY294002 on the adhesion and
Figure 4. Effect of Rac- or PI3K-inhibition on the transmigration of breast cancer cells or melanoma cells through the brain endothelium
in static conditions. MDA-MB-231 breast cancer cells (A, B), A2058 (C, D) or A375 melanoma cells (E) were plated onto conﬂuent D3
monolayers and left for 6 h. Phase-contrast images were made every 5 min and transmigrating tumor cells were counted. Results are
expressed as % control and given as mean § SD. N D 3,  D P < 0.01,  D P < 0.05 as assessed by Student’s t-test.
Figure 5. Effect of Rac- or PI3K-inhibition on the transmigration of
breast cancer cells or melanoma cells through the brain endothe-
lium in dynamic conditions. Results are expressed as % control
and given as mean § SD. N D 3,  D P < 0 .05 EHT1864- or
LY294002-treated cells compared to control, # D P < 0 .05 A2058
cells compared to MDA-MB-231 cells, as assessed by ANOVA and
Bonferroni’s post-hoc test.
6 J. MOLNAR ET AL.
transmigration of breast cancer and melanoma cells was
295 due to toxicity on tumor cells. Using the EZ4U assay no
toxic effect of either EHT1864 or LY294002 on A2058,
MDA-MB-231 and MCF-7 cells was observed (not
shown). Moreover, the EZ4U assay did not show any
toxicity of EHT1864 or LY294002 on D3 brain endothe-
300 lial cells. In addition, as assessed during the time-lapse
video experiments, the number of dividing cells was
approximately 2.5% in case of MDA-MB-231 cells and
1% in case of A2058 cells. Therefore, the observed
changes in the adhesion and transmigration are unlikely
305 to be the result of an anti-proliferative effect of EHT1864
or LY294002. Moreover, the wound healing assay indi-
cated no change in the migratory properties of mela-
noma or breast cancer cells in response to EHT1864 or
LY294002 (not shown).
310 The Rac inhibitor EHT1864 impairs the junctional
integrity of the brain endothelium
We observed that EHT1864 induced a decrease in the
impedance of D3 cells, as reﬂected by the cell index on
Figure 6A. After an initial drop induced by the medium
315 change, the impedance of control and LY294002-treated
D3 cells recovered rapidly. However, in case of
EHT1864-treated cells the recovery was not complete,
and after 5 h a signiﬁcant drop in the impedance was
seen. The cell impedance reﬂects changes in the cell
320 number, viability and tightness of the junctions. Since no
change in the viability of D3 cells was observed using the
EZ4U assay, we next investigated the possible damaging
effect of the Rac inhibitor on the tight junctions. We
observed a signiﬁcant down-regulation of claudin-5 pro-
325 tein in D3 cells in response to EHT1864 (Figure 6B).
LY294002 did not signiﬁcantly affect the amount of clau-
din-5 protein in D3 cells.
Discussion
Brain metastases are devastating complications of lung
330 cancer, breast cancer, melanoma and other malignancies.
Among all solid tumors, melanoma has the highest afﬁn-
ity to the central nervous system. This has been
explained by the speciﬁc brain environment which sup-
ports the growth of cells of ectodermal origin.21,22 How-
335 ever, besides soluble and cellular elements of the central
nervous system, other factors might also contribute to
the neurotropism of melanoma cells.
One of the most important steps in the process of
brain metastasis formation is the diapedesis of metastatic
340 cells through the barriers of the CNS, mainly the BBB-
forming microvascular endothelium. The role of the BBB
in the formation of cerebral metastases is largely
unexplored and probably very complex. Being the tight-
est endothelial barrier in the organism, it hinders the
345transmigration of tumor cells into the brain. On the
other hand, unique brain endothelial properties might
differentially affect the diapedesis of different cancer cell
types.2
Our results indicate that melanoma cells have
350increased adhesion to the brain endothelium than
breast cancer cells. In order to exclude the possibility
that this is due to differences in the invasive and met-
astatic capacities between the melanoma and breast
cancer cell lines used, we used 2 different breast can-
355cer cell lines: the less invasive MCF-7 and the highly
migratory and metastatic MDA-MB-231.14 We also
used 2 different melanoma cell lines, A2058 and
A375, both invasive BRAF V600E mutants, having
similar propensity to metastasize to different organs,23
360A2058 being vemurafenib resistant, while A375
vemurafenib sensitive.24 The difference between the
adhesive properties of melanoma cells and either of
the breast cancer cell lines was signiﬁcant. Moreover,
such a difference was not observed when other endo-
365thelial cell types (HUVECs, dermal microvascular
cells, lymphatic endothelial cells) were used: mela-
noma cells had similar adhesion properties to non-
cerebral endothelial cells as breast cancer cells.25 On
the other hand, incorporation of A375 into HUVECs
370was shown to be faster than that of MDA-MB-321.6
We have also observed a signiﬁcant difference in the
number of transmigrating melanoma and breast can-
cer cells. The number of cells not able to migrate
through the brain endothelium was much higher in
375case of breast cancer cells than in case of melanoma
cells. Moreover, invasive melanoma cells tended to
complete the transmigration process much more rap-
idly than invasive breast cancer cells. These data sug-
gest that tumor cells with higher afﬁnity to the brain
380can more easily overcome the BBB; however, further
studies are needed to support this hypothesis.
Differences between the ability of the 2 tumor cell
types to migrate through the brain endothelium might
be partly due to their different ability to impair the tight
385junctions. Our data indicate that melanoma cells are
more effective in breaking down the paracellular barrier
than breast cancer cells. Breast cancer cells were previ-
ously shown to be able to use not only the paracellular
pathway (through interendothelial junctions), but also
390the transcellular pathway (through the endothelial cell
body) during migration through non-cerebral endothe-
lia.9,10 Our results suggest that breast cancer cells might
be more effective in the transcellular type of migration
than melanoma cells, these latter having increased ability
395to impair the tight junctions than mammary carcinoma
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cells. Further analyses will clarify this possible difference
between the 2 tumor cell types.
We have also assessed the role of 2 signaling mole-
cules (Rac and PI3K) in the transmigration of melanoma
400 and breast cancer cells through the BBB. In a recent
study we showed that melanoma cells prefer the Rac-
dependent mesenchymal type of cell movement to the
Rho/ROCK-dependent amoeboid one during transmi-
gration through the BBB.11 Here we show that inhibition
405 of Rac not only impedes the adhesion and
transmigration of melanoma cells, but of breast cancer
cells as well. According to our previous results, ROCK
inhibition induced an increase in the adhesion force
between melanoma and brain endothelial cells. We
410hypothesized that mesenchymal cell ﬂattening was partly
responsible for this phenomenon.11 We suppose that
induction of the amoeboid phenotype using the Rac
inhibitor does not have such a signiﬁcant impact on the
shape of tumor cells detached from the surface. There-
415fore, the area of contact between tumor cells and
Figure 6. Effect of the Rac inhibitor EHT1864 on the junctional integrity of the brain endothelium. (A) The impedance of D3 brain endo-
thelial cells (represented by the cell index) was assessed by the ACEA xCELLigence system. Results are expressed as % control and given
as mean§ SD. ND 3, D P< 0.05 compared to control, as assessed by ANOVA and Bonferroni’s post-hoc test. (B) D3 cells were treated
with 20 mM EHT1864 or 25 mM LY294002 for 5 h. Claudin-5 western-blot was performed from the RIPA-soluble fraction. One representa-
tive blot and densitometry based on 3 independent experiments is shown.  D P < 0.05 compared to control, as assessed by ANOVA
and Bonferroni’s post-hoc test.
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endothelial cells does not signiﬁcantly differ between
control and Rac-inhibited tumor cells, resulting in simi-
lar adhesion forces in the presence or absence of
EHT1864, as measured by AFM.
420 Interestingly, the ROCK inhibitors Y27632 or fasudil
– which signiﬁcantly facilitated the adhesion of mela-
noma cells11 – did not affect the adhesive properties of
breast cancer cells. However, the effect of Rac inhibition
was similar in case of both melanoma and breast cancer
425 cells: a signiﬁcant decrease in the number of tumor cells
attaching to and transmigrating through cerebral endo-
thelial cells was observed. This supports the idea that
inhibition of the mesenchymal movement of tumor cells
might be beneﬁcial in reducing the diapedesis of different
430 metastatic cells through the BBB. Unfortunately, Rac
inhibitors – in contrast to ROCK inhibitors, which pre-
vent the disruption of the tight junctions of CECs –
might impair the integrity of the BBB.
Besides Rac, we tested the role of the PI3K/Akt/PTEN
435 pathway, which is a key regulator of tumorigenesis and
metastasis formation. BRAF-mutant melanoma cells
have been shown to have higher levels of pAkt-Ser473,
pAkt-Thr308 and decreased expression of PTEN.26 The
A2058 cell line used in our experiments is a V600E
440 BRAF mutant expressing high amounts of phosphory-
lated Akt and low levels of PTEN.27 It has been shown
that inhibition of PI3K results in a reduction of mela-
noma cell transmigration through HUVECs.28 Since
brain metastases of melanoma have been shown to have
445 signiﬁcantly higher pAkt and lower PTEN levels than
extracerebral metastases,26,29 we aimed to test whether
inhibition of this pathway impedes the transmigration of
melanoma cells through CECs. We observed a marked
inhibition of melanoma cells able to attach to and to
450 migrate through the brain endothelium in response to
PI3K inhibition. This is in contrast with small cell lung
cancer cells, which were not affected by PI3K inhibition
in their transmigration through brain microvascular
endothelial cells.30 It has been previously shown that
455 inhibition of Rac or PI3K, but of ROCK also reduces the
pulmonary microvascular endothelial cell-induced inva-
siveness of MDA-MB-231 with high a5b1 integrin
expression.31 According to our results, breast cancer cell
transendothelial migration could be partly blocked using
460 the PI3K inhibitor LY294002 – similarly to melanoma
cells.
The morphology of PI3K-inhibited tumor cells was
similar to that of Rac-inhibited cells, i.e., we could see a
reduction in the number of elongated, ﬂattened cells.
465 This suggests that PI3K inhibition – similar to Rac inhi-
bition – induces an amoeboid-like phenotype in both
melanoma and breast cancer cells. This is not surprising
because PI3K has been shown to regulate Rac through P-
Rex1 in breast cancer cells15 and several PI3K lipid prod-
470ucts have been shown to interact with different
RacGEFs.32
In contrast to EHT1864, the PI3K inhibitor LY294002
did not affect the integrity of the BBB. Moreover, many
PI3K inhibiting agents are in different phases of clinical
475trials for the treatment of different cancer types.33 Based
on our results, PI3K inhibitors might turn out to have
clinical beneﬁts not only in the treatment of primary
tumors, but also in preventing brain metastasis forma-
tion of breast cancer and melanoma cells.
480In conclusion, we have shown that invasive melanoma
cells have an increased capacity to attach to, to migrate
through and to impair the tight junctions of the brain
endothelium than breast cancer cells. In addition, inhibi-
tion of Rac or PI3K decreases the number of both mela-
485noma and breast cancer cells able to transmigrate
through cerebral endothelial cells; however, Rac inhibi-
tion (but not PI3K inhibition) impairs the junctional
integrity of the blood-brain barrier. Since inhibitors of
the PI3K/Akt pathways are emerging as candidates for
490anti-cancer therapy, the mechanism described here
might be of clinical relevance.
Materials and methods
Cell culture and treatments
MDA-MB-231 and MCF-7 human breast cancer cells
495were kept in DMEM medium (Sigma) supplemented
with 5% FBS (Lonza). A2058 human melanoma cells
(obtained from the European Collection of Cell Cultures)
were maintained in EMEM (Sigma) supplemented with
5% FBS (Sigma). A375 human melanoma cells were kept
500in DMEM medium (Sigma) supplemented with 10% FBS
(Lonza). The hCMEC/D3 human microvascular cerebral
endothelial cells (abbreviated as D3) were grown on rat
tail collagen-coated dishes in EBM-2 medium (Lonza)
supplemented with EGM-2 Bullet Kit (Lonza) and 2.5%
505FBS (Sigma). Rat brain endothelial cells (RBECs) used
for immunoﬂuorescence experiments were isolated and
cultured as described previously.34
ROCK inhibitors (Y27632, Tocris and fasudil, Santa
Cruz) were used in a ﬁnal concentration of 10 mM.
510EHT1864 (Tocris), an inhibitor of Rac family GTPases,
was applied in a 20 mM concentration. LY294002 (Cell
Signaling Technology) – a reversible and highly selective
inhibitor of phosphatidylinositol 3 kinase (PI3K) – was
used in a concentration of 25 mM.
515Adhesion experiments
Brain endothelial cells (D3) were grown until conﬂuence
in 24-well plates. Tumor cells (MDA-MB-231, MCF-7 or
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A2058 cells) were ﬂuorescently labeled using Oregon
Green 488 carboxylic acid diacetate succinimidyl ester or
520 Cell Tracker red (Life Technologies) using the protocol
supplied by the manufacturer. 5 £ 104 tumor cells/well
were plated onto the endothelial monolayer in serum-
free medium and incubated for 90 min. Non-attached
cells were washed and the remaining cells were ﬁxed
525 using ethanol/acetic acid (95/5) at ¡20C for 5 min.
Tumor cells adhered to endothelial cells were photo-
graphed and counted using the Image-Pro Plus software
(Media Cybernetics).
Adhesion force measurements
530 Single cell force spectroscopy measurement of adhesion
forces between tumor cells and endothelial cells using
atomic force microscopy (AFM) was performed as previ-
ously described in details.11
Static transmigration experiments using time-lapse
535 video imaging
Human cerebral endothelial cells (D3) were cultured
until conﬂuence in 12-well plates. 2 £ 104/well tumor
cells were plated onto the endothelial monolayer in Lei-
bovitz’s L-15 medium (Sigma). Cells were monitored for
540 6 h using an Andor NEO sCMOS camera connected to a
Nikon Eclipse Ti-E inverted microscope, equipped with
a home built incubator set to 37C. Phase-contrast
images were made every 5 min from 5 optical ﬁelds/well
and time-lapse videos were constructed. The movement
545 of each tumor cell was evaluated and transmigrated cells
were counted.
Dynamic transmigration experiments using
microﬂuidics
Design and fabrication of microdevices
550 To investigate the transmigration of tumor cells under
low shear stress conditions we designed and constructed
a biocompatible artiﬁcial capillary network. The sche-
matic representation of the microﬂuidic setup is shown
in Figure 1A. The microﬂuidic capillary device was fabri-
555 cated from poly-dimethylsiloxane (PDMS, Sylgard 184,
Dow Corning Corp.) using standard photolithography
and soft lithography techniques.35 Imprints of the micro-
devices were built by creating 100 mm high SU8–2050
negative photoresist (MicroChem Corp.) layers on sili-
560 con wafers. The photoresist layers were exposed to UV
light through a chromium mask (JD Photo-Tools Ltd.),
using a ﬂood exposure source with mask aligner (500W
Hg lamp, i-line, model 97435, Newport Corp. & Digital
Exposure Controller model 68945, Newport Corp.). In
565order to prevent the attachment of PDMS to the SU8
molds, the molds were treated with tridecaﬂuoro-1,1,2,2-
tetrahydrooctyl-trichlorosilane (Gelest Inc.) under vac-
uum overnight. Positive replicas were fabricated by
PDMS molding. The PDMS replicas were cured, inlet
570holes and bubble traps were punched and the devices
were bound to PDMS-covered microscope glass slides
using oxygen plasma treatment.
Cell seeding and microﬂuidic cell culture
Prior to seeding of brain endothelial cells, the inner sur-
575face of the channels was coated with rat tail collagen. 106
D3 cells were collected in 100 ml Leibovitz’s L-15 media
completed with 2.5% FBS (Sigma), growth factor mix
(Lonza), hydrocortisone and gentamicin-amphotericin-B
and injected into the microchannels. The microﬂuidic
580devices were placed in a home built incubator installed
on a microscope stage set to 37C. Cells were kept in
“static conditions” for 24–36 h to reach a conﬂuent layer.
During this static state the D3 medium was refreshed
every 8 h. When the conﬂuent endothelial layer fully
585developed, a continuous ﬂow at 300 ml/h rate was started
and maintained for 24 h to mimic the blood circulation.
During the transmigration experiments 3 £ 105 tumor
cells were collected in 100 ml media and injected manually
(with syringe). After the injection, a continuous ﬂow with
590100ml/h rate was established and maintained for 6 h. Con-
sidering the physical parameters of the device (channel
height of»100 mm, channel width of»240–480 mm) and
the used ﬂuid ﬂow rates (100–300 ml/h), we can estimate
the shear stress (based on36) acting on the endothelial cells
595in the microchannels. The applied ﬂuid ﬂow generated a
low stress regime in our device, in which the shear stress
was around»0.3–2 dyn/cm2.
Microscopy
Phase contrast microscopy images were taken during the
600cell culturing and the transmigration experiments, using
an Andor NEO sCMOS camera and a Nikon Eclipse Ti-
E microscope (Nikon Inc.), equipped with a 20£ Plan
Fluor phase contrast objectives and a Proscan II motor-
ized microscope stage (Prior Scientiﬁc Ltd.). We used the
605Nikon NIS Elements AR software (Nikon Inc.) to control
the microscope setup during the recordings. Microscopy
images were taken every 30 min during the endothelial
cell attachment phase and every 5 min during the trans-
migration experiments (representative images are shown
610on Figure 1B).
Image analysis
We followed each individual tumor cell in 6 ﬁelds/micro-
channel. Total number of cells counted was considered
100% in case of each microchannel. Cells were classiﬁed
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615 in one of the following groups: “no attachment” (cells
washed away by the ﬂow of the culture medium in early
stages of the experiment), “no transmigration” (cells
remaining attached to the endothelial layer but not able
to transmigrate in 6 h), “transmigr. in 20 min” or “trans-
620 migr. in >20 min”. Comparison was performed among
the four groups in case of each cell type and each treat-
ment, among control and EHT1864- or LY294002-
treated breast cancer or melanoma cells and among
breast cancer and melanoma cells. Statistical analysis was
625 performed using ANOVA and Bonferroni’s post-hoc
test.
Immunoﬂuorescence
RBECs were cultured until conﬂuence on collagen/ﬁbro-
nectin-coated ﬁlter inserts. Tumor cells (MDA-MB-231
630 or A2058) were ﬂuorescently labeled using Cell Tracker
red (Life Technologies) and plated onto the endothelial
monolayer. After 5 h cells were washed and ﬁxed with
ethanol/acetic acid. After blocking with 3% BSA, cover-
slips were incubated with anti-claudin-5 primary anti-
635 body (Life Technologies). The staining was visualized
using a Alexa488-conjugated secondary antibody. Nuclei
were stained with Hoechst 33342. Samples were
mounted in FluoroMount-G (SouthernBiotech) and
studied with a Nikon Eclipse TE2000U microscope con-
640 nected to a digital camera (Spot RT KE, Diagnostic
Instruments).
Cell viability assay
Viability of tumor cells and endothelial cells was quanti-
ﬁed with the EZ4U non-radioactive cell proliferation and
645 cytotoxicity assay (Biomedica). D3, MDA-MB-231 and
MCF-7 cells were seeded in 96-well plates. Next day the
cells were treated for 5 h with 20 mM EHT1864 or
25 mM LY294002 in serum-free, phenol-red free
DMEM. After incubation with EZ4U substrate for
650 45 min, the absorbance (OD at 450 nm) was detected
using a BMG FLUOstar OPTIMA microplate reader.
Wound healing assay
Tumor cells (MDA-MB-231, MCF-7 or A2058) were
seeded into 24-well plates. After attachment the cell layer
655 was wounded by scratching with a pipette tip, washed
with PBS, and exposed to treatments with 20 mM
EHT1864 or 25 mM LY294002 in serum-free Leibovitz’s
L-15 medium. Cells were monitored over 24 h, and phase
contrast images were taken every 30 min with an Andor
660 NEO sCMOS camera connected to the Nikon Eclipse Ti-
E inverted microscope equipped with a home-built
incubator set to 37C and a 20£ Nikon Plan Fluor objec-
tive, all placed onto a Prior Proscan II motorized stage
(Prior Scientiﬁc Instruments). The wound healing effect
665was quantiﬁed by averaging the number of migrating
cells counted in 5 wounded areas.
Real-time impedance monitoring
To monitor the effects of EHT1864 and LY294002 on D3
cells in real-time, we measured the electrical impedance
670using the xCELLigence system following the manufac-
turer’s instructions (Acea Biosciences Inc.). Brieﬂy, cells
were seeded at a density of 104 cells/well into 100 ml of
media in an E-Plate (i.e., 96-well tissue culture plates
having micro-electrodes integrated on the bottom) and
675allowed to attach onto the electrode surface over time.
The electrical impedance was recorded every 15 min.
When the impedance reached plateau (i.e., conﬂuent
monolayer with well-formed junctions), the cells were
treated with 20 mM EHT1864 or 25 mM LY294002 for
680an additional 10 h. The cell impedance (which depends
on cell number, degree of adhesion, spreading and prolif-
eration of the cells and also the tightness of the junc-
tions), expressed in arbitrary units (cell index) was
automatically calculated by the software of the
685instrument.
Western-blot analysis
Conﬂuent D3 brain endothelial cells were treated with
20 mM EHT1864 or 25 mM LY294002 for 5 h. Cells were
washed with PBS and scraped into ice-cold RIPA buffer
690(20 mM Tris, 150 mM NaCl, 0.5% Triton X-100, 1%
sodium deoxycholate, 0.1% sodium dodecyl sulfate,
1 mM sodium vanadate, 10 mM NaF, 1 mM EDTA,
1 mM Pefabloc) and incubated on ice for 30 min. Lysates
were clariﬁed by centrifugation at 10,000 g for 10 min at
6954C. Proteins were electrophoresed and blotted onto
nitrocellulose (Bio-Rad) membranes. Blocking was car-
ried out at room temperature for 30 min in TBS-T con-
taining 3% BSA. Anti-claudin-5 (Invitrogen), primary
antibody was used. After washing the membranes in
700TBS-T, blots were incubated with the HRP-conjugated
secondary antibody diluted in TBS-T. The immunoreac-
tion was visualized using Clarity ECL Western Blot Sub-
strate kit (Bio-Rad) in a Bio-Rad ChemiDoc MP Imaging
System.
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